MiMedx Group Stock Forecast for 2023 - 2025 - 2030
Updated on 05/02/2024
MiMedx Group Stock Forecast and Price Target
Given the average yearlong price target of $12.00 provided by prominent analysts over the past few months, there is a potential upside of approximately 64.16% from the last closing price in May, 2024 for MiMedx Group's stock if it is reached. This estimation is based on a high estimate of $14.00 and a low estimate of $10.62. You may be interested in rivals even if you aren't interested in MiMedx Group stock.
64.16% Upside
MiMedx Group Fair Value Forecast for 2023 - 2025 - 2030
In the last three years, MiMedx Group's Price has grown, moving from $0.00 to $0.00 – an increase of 100.00%. In the next year, analysts predict that Fair Value will jump to $7.85 – up 100.00% from the current level. Looking ahead to seven years, experts forecast that Fair Value will grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| SYK Stock Forecast | Stryker Corp | Outperform |
10
|
$328.12 | Buy/Sell | $353.16 | 12.31% |
| MDT Stock Forecast | Medtronic | Outperform |
11
|
$80.89 | Buy/Sell | $92.47 | 18.06% |
| BDX Stock Forecast | Becton Dickinson and Co | Outperform |
9
|
$233.72 | Buy/Sell | $284.47 | 18.73% |
| ZBH Stock Forecast | Zimmer Biomet Holdings | Hold |
15
|
$119.56 | Buy/Sell | $132.52 | 13.75% |
| SN. Stock Forecast | Smith & Nephew | Outperform |
18
|
£9.77 | Buy/Sell | £16.09 | 67.96% |
MiMedx Group Revenue Forecast for 2023 - 2025 - 2030
In the last three years, MiMedx Group's Revenue has grown, moving from $248.23M to $321.48M – an increase of 29.51%. In the next year, analysts predict that Revenue will jump to $355.70M – up 10.64% from the current level. Looking ahead to seven years, experts forecast that Revenue will grow by 50.50%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| PEN Stock Forecast | Penumbra | Outperform |
9
|
$205.29 | Buy/Sell | $258.62 | 39.83% |
| CTEC Stock Forecast | ConvaTec Group PLC | Outperform |
16
|
£2.46 | Buy/Sell | £3.43 | 61.38% |
| ENOV Stock Forecast | Enovis | Buy |
15
|
$55.40 | Buy/Sell | $70.50 | 35.38% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| VCEL Stock Forecast | Vericel | Buy |
8
|
$47.08 | Buy/Sell | $42.58 | 16.82% |
| OFIX Stock Forecast | Orthofix Medical | Hold |
10
|
$13.03 | Buy/Sell | $18.00 | 15.12% |
| ORGO Stock Forecast | Organogenesis Holdings | Outperform |
10
|
$2.51 | Buy/Sell | $4.75 | 99.20% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| AXGN Stock Forecast | AxoGen | Buy |
6
|
$6.56 | Buy/Sell | $12.50 | 113.41% |
| ANGO Stock Forecast | AngioDynamics | Buy |
8
|
$5.79 | Buy/Sell | $16.33 | 124.53% |
| RCEL Stock Forecast | AVITA Medical | Buy |
6
|
$8.65 | Buy/Sell | $37.39 | 290.98% |
MiMedx Group EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, EBITDA for MiMedx Group has grown by 208.05%, going from $-37.52M to $40.54M. In the coming year, analysts are expecting an increase in EBITDA, predicting it will reach $69.45M – an increase of 71.31%. Over the next seven years, experts anticipate that EBITDA growth for MiMedx Group will be 120.69%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| LCTX Stock Forecast | Lineage Cell Therapeutics | Outperform |
11
|
$1.13 | Buy/Sell | $5.40 | 342.48% |
| MSB Stock Forecast | Mesoblast | Buy |
9
|
$1.10 | Buy/Sell | $0.69 | 0.00% |
| CGEN Stock Forecast | Compugen | Buy |
7
|
$1.99 | Buy/Sell | $4.00 | 151.26% |
MiMedx Group EBIT Forecast for 2023 - 2025 - 2030
MiMedx Group's EBIT has grown in the last three years, jumping from $-44.37M to $37.12M – an increase of 183.66%. In the next year, analysts predict that EBIT will reach $60.24M – an increase of 62.28%. For the next seven years, the forecast is for EBIT to grow by 254.38%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| XTNT Stock Forecast | Xtant Medical Holdings | Buy |
0
|
$0.86 | Buy/Sell | $1.93 | 124.42% |
| RWLK Stock Forecast | ReWalk Robotics | Outperform |
9
|
$4.75 | Buy/Sell | $3.00 | 1226.32% |
| AURX Stock Forecast | Nuo Therapeutics | - |
0
|
$0.80 | Buy/Sell | $0.00 | -100.00% |
MiMedx Group EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last three years, MiMedx Group's EPS has grown, moving from $-0.07 to $0.00 – an increase of 100.00%. In the next year, analysts predict that EPS will jump to $0.32 – up 100.00% from the current level. Looking ahead to seven years, experts forecast that EPS will grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| PLUR Stock Forecast | Pluri | - |
9
|
$5.37 | Buy/Sell | $4.00 | -100.00% |
| EKSO Stock Forecast | Ekso Bionics Holdings | Outperform |
0
|
$1.92 | Buy/Sell | $11.00 | 368.75% |
| SNWV Stock Forecast | SANUWAVE Health | - |
-12
|
$0.02 | Buy/Sell | $0.34 | -100.00% |
.jpg)